Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Virus Genes ; 57(4): 327-337, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34091827

ABSTRACT

Argentina exhibits low serological prevalence for Hepatitis B virus (HBV); however, occult hepatitis B infection (OBI) has been reported in blood donors, Amerindians and individuals coinfected with hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV). The aim of this study was to analyze the genetic diversity of HBV and to evaluate serological marker associations and coinfections with HCV and HIV in patients attending and treated in a public hospital in the province of Buenos Aires, Argentina. A total of 189 HBV reactive samples (HBsAg and/or anti-HBc) were analyzed for HBV DNA characterization. All reactive samples were tested for anti-HCV and HIV-antigen/antibody using CMIA assays. Thirty-six samples exhibited detectable HBV DNA, 7 of which were OBI. HBV sequences were classified as subgenotypes A1, A2, B2, D3, F1b, F3 and F4. Mutations related to the ability to escape the host's immune response, resistance to antiviral therapy and progression to disease were found in patients, partly due to the variable sensitivity of HBsAg, the reverse transcriptase, the basal core promoter and the preCore. HCV and HIV prevalence was 10% and most of the genotypes found in the sequences were genotype 1 and B/F recombinant subtype, respectively. Of the total samples analyzed, 7 exhibited coinfections. This study shows the frequency of OBI, subgenotype distribution, HBV mutations and coinfections, which may have important clinical implications in public hospital patients. Planned prevention, detection and treatment adherence are needed to reduce transmission and morbidity in vulnerable populations.


Subject(s)
Coinfection/genetics , Hepatitis B, Chronic/genetics , Hepatitis B/genetics , Hepatitis C/genetics , Adolescent , Adult , Aged , Argentina/epidemiology , Blood Donors , Coinfection/blood , Coinfection/drug therapy , Coinfection/virology , Drug Resistance, Viral/genetics , Female , Genotype , HIV Infections/blood , HIV Infections/genetics , HIV Infections/virology , Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatitis B/blood , Hepatitis B/drug therapy , Hepatitis B/virology , Hepatitis B Antibodies/blood , Hepatitis B Antibodies/immunology , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/genetics , Hepatitis B Surface Antigens/immunology , Hepatitis B virus/genetics , Hepatitis B virus/pathogenicity , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Hepatitis C/blood , Hepatitis C/drug therapy , Hepatitis C/virology , Hospitals, Public , Humans , Male , Middle Aged , Mutation/genetics , Occult Blood , Young Adult
2.
J Pharm Pharmacol ; 71(11): 1655-1662, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31456253

ABSTRACT

INTRODUCTION: Hepatocellular carcinoma is the most common liver malignancy and the third leading cause of cancer death worldwide. One crucial limitation in the pharmacotherapy for this tumour is its chemotherapy-resistant nature produced by the overexpression of several members of the ATP-binding cassette protein family that efflux drugs out of cells, as observed with the breast cancer resistant protein (BCRP). OBJECTIVES: This study aimed to assess the ability of Pluronic® F127 to reverse the multidrug resistance phenotype in two human hepatocellular cell lines. METHODS: PLC/PRF/5 and SKHep1 cells were exposed to Pluronic® F127 at several concentrations. The effect of F127 on BCRP expression (mRNA and protein), mitochondrial transmembrane potential and cell hypodiploidy was assessed. Finally, the effect of this copolymer on cytotoxicity of doxorubicin in both hepatoma cell lines was investigated, as expressed by its reverse resistance index. KEY FINDINGS: It was demonstrated that F127 in both cell lines contributes to chemosensitization, as shown by BCRP down-regulation, an altered mitochondrial transmembrane potential and hypodiploidy and reverse resistance index values. A remarkable dependence of these effects significantly correlated with the copolymer concentration. CONCLUSIONS: These findings further uncover the potential usefulness of this copolymer as multidrug resistance reversal agent, increasing the efficacy of cancer therapies.


Subject(s)
Doxorubicin/blood , Doxorubicin/pharmacology , Poloxamer/chemistry , Polyethylenes/chemistry , Polypropylenes/chemistry , ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , Carcinoma, Hepatocellular/drug therapy , Cell Line, Tumor , Down-Regulation/drug effects , Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Liver Neoplasms/drug therapy , Membrane Potential, Mitochondrial/drug effects
3.
Biotechnol Appl Biochem ; 63(2): 273-80, 2016.
Article in English | MEDLINE | ID: mdl-25630439

ABSTRACT

UNLABELLED: Recent data have shown that synthetic polymers and nanomaterials display phenotypic effects in cells and signal transduction mechanisms involved in inflammation, differentiation, proliferation, and apoptosis. AIM: This article aims to investigate the effect of poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO) block copolymers with a wide range of biomedical and pharmaceutical applications on apoptosis and/or cell immortalization, by flow cytometry and multiplex RT-PCR for bax, bcl-2, and human telomerase reverse transcriptase (hTERT). RESULTS: PEO-PPO amphiphiles upregulated bax and hTERT and induced apoptosis of two human hepatoma cell lines. CONCLUSIONS: PEO-PPO block copolymers-considered safe for human use-can drastically alter gene expression profiles of genes related to apoptosis/cell proliferation.


Subject(s)
Apoptosis/drug effects , Carcinoma, Hepatocellular/pathology , Polyethylenes/pharmacology , Polypropylenes/pharmacology , Proto-Oncogene Proteins c-bcl-2/genetics , Surface-Active Agents/pharmacology , Telomerase/genetics , bcl-2-Associated X Protein/genetics , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Carcinoma, Hepatocellular/drug therapy , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Polyethylenes/chemistry , Polypropylenes/chemistry , RNA, Messenger/genetics , RNA, Messenger/metabolism , Surface-Active Agents/chemistry , Tumor Cells, Cultured
4.
Arch Virol ; 159(5): 1109-17, 2014 May.
Article in English | MEDLINE | ID: mdl-24306325

ABSTRACT

In Argentina, current procedures to ensure the safety of the blood supply for transfusion include the serologic detection of specific blood-borne infections. The aim of this study was to evaluate the prevalence and the genetic diversity of hepatitis B virus (HBV) and hepatitis D virus (HDV) in blood donor populations from two distantly located Argentine regions. Data from 56,983 blood donations from the Favaloro Foundation, in the city of Buenos Aires (Central Region), and the Central Blood Bank of Misiones Province (Northeast Region) were analyzed. Samples that were reactive for HBsAg were analyzed for HBV-DNA characterization and HDV serological and molecular analysis. The HBV prevalence was 0.12 % for HBsAg and 1.68 % for anti-HBc antibodies in Buenos Aires, and 0.73 % and 8.55 %, respectively, in Misiones. Seventy-seven HBsAg-reactive samples were analyzed by polymerase chain reaction for HBV-DNA. Subgenotypes A2, B2, C2, F1b and F4 (Buenos Aires) and F1b and D3 (Misiones) were detected. Several mutations within the major hydrophilic region of HBsAg, the reverse transcriptase, the basal core promoter, and the precore/core were detected. HDV genotype 1 was identified in Buenos Aires. This study confirms the circulation of several HBV subgenotypes, as well as known and newly identified variants, and the presence of HDV1 in this population. A thorough investigation has to be carried out to evaluate the clinical importance of some of the documented mutations as well as those detected in the HDV1 case.


Subject(s)
Blood Donors , Hepatitis B Surface Antigens/blood , Hepatitis B virus/isolation & purification , Hepatitis Delta Virus/isolation & purification , RNA-Directed DNA Polymerase/metabolism , Argentina/epidemiology , Cloning, Molecular , DNA, Viral/genetics , Gene Expression Regulation, Enzymologic/physiology , Gene Expression Regulation, Viral/physiology , Hepatitis B/blood , Hepatitis B/epidemiology , Hepatitis B/virology , Hepatitis B Surface Antigens/genetics , Hepatitis D/blood , Hepatitis D/epidemiology , Hepatitis D/virology , Humans , Mutation , Phylogeny , Polymorphism, Restriction Fragment Length , RNA-Directed DNA Polymerase/genetics
5.
J Gen Virol ; 88(Pt 1): 86-91, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17170440

ABSTRACT

The intrahost hepatitis B virus (HBV) genomic evolution process of an HBe antigen (HBeAg)-negative chronic HBV patient (designated RI) was studied. Two nearly full-length direct sequences obtained in 1995 (RI95) and 1998 (RI98) showed: (a) a mutation rate of 2.7x10(-3) nucleotides per site per year; (b) nucleotide changes mainly located at single coding regions (P=0.002); (c) mixed populations; and (d) a predominance of non-synonymous substitutions (P=0.0036). Population heterogeneity was assessed by cloning and sequencing of a fragment spanning nearly half the genome. Two-thirds of the analysed clones exhibited long nucleotide deletions. Pairwise genetic diversity revealed that diversity was higher for RI95 than for RI98 cloned sequences. In conclusion, a highly heterogeneous genomic population circulated within patient RI, which might support the persistence of HBV. Finally, the structure of the deletant genomes suggests that they might serve as intermediates for integration to the host-cell genome.


Subject(s)
Genome, Viral , Hepatitis B e Antigens/metabolism , Hepatitis B virus/classification , Evolution, Molecular , Genotype , Hepatitis B e Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/isolation & purification , Humans , Longitudinal Studies , Male , Middle Aged , Phylogeny , Retrospective Studies
6.
J Virol Methods ; 136(1-2): 58-64, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16716411

ABSTRACT

Although GB virus C (GBV-C) hepatocyte pathogenicity is still controversial, it appears that at least some strains of this virus are lymphotropic. During the past few years, several reports have documented an apparently beneficial role played by GBV-C in the course of HIV-1 infection. At present, a commercial kit for GBV-C RNA quantitation is not available. In this study, a competitive RT-PCR method for GBV-C in serum samples is described. The sensitivity of the assay proved to be 10(4) and 10(3) genomic equivalents for positive and negative sense RNAs, respectively. This method will discriminate specifically between positive and negative strand RNAs with a discrimination index of at least five log10. Out of 60 samples from different hematological disorders (n = 49), HIV-1 positive patients (n = 7), and blood donors (n = 4), 10 proved to be GBV-C RNA positive. Viral load ranged from 1.1 x 10(7) to 2.34 x 10(8) genomic equivalents/ml. Such values correlated linearly (r = 0.986) with those obtained by a 10-fold serial dilution method. In studies exploring the GBV-C pathogenicity, the measurement of viral load may contribute to understand the possible mechanisms involved.


Subject(s)
GB virus C/isolation & purification , RNA, Viral/blood , Reverse Transcriptase Polymerase Chain Reaction/methods , Humans , RNA, Viral/genetics , Sensitivity and Specificity , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...